Dataset ID: 5
Back to List

Dataset Details

Study Design
Study Design Background Assessment of the uptake of a novel CXCR-4 directed radiolabelled peptide in naive and tumor bearing animals.
Study Description CXCR4
Study Type Preclinical
Study Subtype In vitro and in vivo
Publication
Paper Linked Yes
Paper Title D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
Paper Authors Kaat Luyten(1), Tom Van Loy(256), Christopher Cawthorne(3), Christophe M. Deroose(3), Dominique Schols(256), Guy Bormans(1) and Frederik Cleeren(1)
Affiliation Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven; 3000 Leuven, Belgium
Paper Journal Pharmaceutics
Paper Year 2022
Paper DOI https://doi.org/10.3390/pharmaceutics13101619
Open Access Yes
Study Component
Multi Modality Images Yes
Imaging Modality PET CT
NCIT Imaging
Radiation Yes
Imaging Coverage Whole body
Imaging Target CXCR4
Dataset Information
Institution KU Leuven
PI Frederik Cleeren
Country Of Institution Belgium
Imaging Facility Molecular Small Animal Imaging Centre (MoSAIC), KU Leuven
Euro Bio Imaging Node Flanders Bio Imaging (Candidate EuBI node)
Country Of Imaging Facility Belgium
In Vivo Experimental Parameters
Number Of Groups 2
Types Of Groups Naive animals - + CXCR4 blocking drug
Overall Sample Size 9
Disease Model Healthy animals
Organ Or Tissue Liver, kidneys
NCIT Anatomy
Sample Size For Each Group 5 animals for tracer uptake, 4 animals for tracer uptake + blocking compound
Power Calculation The number of animals included in the study was based on previous reports where an approximately 70% difference was seen between naïve and blocked animals in CXCR4 expressing organs [https: jnm.snmjournals.org content 61 1 123]. Detection of such difference therefore required 3 animals per group (power = 0.95 and a = 0.05) assuming a 20% standard deviation within the groups.
Randomization Yes. All animals included in the study were randomly selected among the in-house bred mice of the correct age.
Blinding No
Outcome Measures Time activity curves showing uptake in kidneys and liver over the 1hr scan period - + blocking agent
Statistical Methods One tail t-test for independent groups assuming unequal variances
Species Mice
NCIT Species
Strain NMRI
NCIT Strain
Immune Status Immune competent
Sex Female
Age 5 weeks on arrival
Age At Start Experiment 30 weeks
Age At Scanning Experiment S 30-32 weeks
Weight At Start Experiment 35-45g
Weight At End Experiment 35-45g
Source Of Animals Envigo (Netherlands)
Experimental Procedures
Pharmacological Procedures Intervention And Control Yes
Pharmacological Drug AMD3100
CHEBI Pharmaco
Formulation PBS
Drug Dose 5mg kg
Site Or Route Of Administration Iv
Frequency Of Administration Once, at the start of scanning
Vehicle Or Carrier Solution Formulation PBS
Blood Sampling No
Surgical Procedures Including Sham Surgery No
Pathogen Infection Intervention And Control No pathogens used
Analgesic Plan To Relieve Pain Suffering And Distress No
CHEBI Anesthesia
Anesthesia Type Gas
Duration 75-90
Anesthesia Drugs Isoflurane
Anesthesia Dose 1-2%
Monitoring Regime Respiratory and temperature monitoring whilst scanning, visual surveillance during preparation and recovery
Euthanasia Yes
Method Cervical dislocation
Histology No
Frequency Of Imaging Single scan
Timing Of Imaging Animals scanned in accordance with radiotracer production schedule
Overall Scan Length 60 minute PET + CT
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule Yes
Contrast Agent Commercial Drug None, Pentixafor
Contrast Agent Chemical Drug [18F]AlF-NOTA-DV1-k-(DV3),
Contrast Agent Dose 1.5-3.0MBq
Injection Volume 0.15-0.225ml
Injection Time 8-10 seconds
Vehicle Saline
Route Of Administration Intravenous
Housing Room Not SPF
Respiration Rate Only during scanning
Body Tempurature Etc Only during scanning
Food Intake Measured No
Image Data
Image Type Processed images (reconstructed PET and CT data)
Image Scale HU for CT, SUV for PET
Format Compression DICOM
Dimensions 3D
Overall Number Of Images 3 x PET, 3 x CT for original images, 9 individual images
Field Of View 70x70x124.8 (CT); 76.8x76.8x 153.6 (PET) for multiple animal image; individual cropped images vary
Dimension Extents 350x350x624 (CT); 192x192x384 (PET) for multiple animal image; individual cropped images vary
Size Description 70x70x124.8 (CT); 76.8x76.8x 153.6 (PET) for multiple animal image; individual cropped images vary
PI xel Voxel Size Description 0.2mm (CT), 0.4mm (PET)
Image Processing Methods Images reconstructed as below.
Image Reconstruction Algorithm OSEM (PET), 30 iterations. Iterative (CT)
QC Info QC: high (injections all successful as evidenced by dynamic images)
Corrections Corrections listed above
Image Correlation
Spatial And Temporal Alignment PET and CT images aligned using rigid registration in PMOD 4.0.
Coregistered Images Dataset includes coregistered datasets for individual animals
Transformation Matrix Other Info Transformation matrix not saved, but original multiple-animal images available
Related Images And Relationship PET and CT images aligned using rigid registration in PMOD 4.0.
Analyzed Data
Analysis Result Type Numerical
Data Used For Analysis Time activity curves generated by manual delineation of kidneys and a sphere centred on the liver, scaled to SUV
Analysis Method And Details Manual delineation of organs placement of spherical ROIs in PMOD v 4.0.
Status Complete
Updated Year 2022